Adocia SAS Faces a 3.5 % Decline in the Latest Trading Session
Adocia SAS (ticker ADOC.PA) closed the most recent 24‑hour trading window at 02:58 PM Central Europe on Friday, 23 October, down 3.52 %. The share price settled at approximately €2.42 on the major exchanges, reflecting a broader decline that has persisted since the end of last month when the stock fell 34.63 %.
With a current market capitalization of €52.3 million and a supply of 20.4 million shares, Adocia’s liquidity remains modest. In the last 24 hours, roughly €1 million of the company’s shares exchanged hands, indicating a limited but active trading volume. The 200‑day simple moving average sits at €4.63, suggesting that the stock is trading below its recent trend line.
Over the past year, Adocia’s price has oscillated dramatically: the high of €9.76 was recorded on 29 October 2025, while the 52‑week low of €2.01 appeared on 8 October 2026. The current price of €2.42 therefore places the share within the lower quartile of its recent range, underscoring the volatility investors have faced.
Comparative Performance of Peer Companies
| Company | 24‑Hour Movement | Current Price (EUR) | Market Cap (EUR) | P/E Ratio |
|---|---|---|---|---|
| Groupe Ldlc (ALLDL.PA) | +1.16 % | 8.44 | 58.3 million | 5.27 |
| Hotelim (MLHOT.PA) | 0 % | 53.5 | 56.4 million | – |
| Catana (ALCAT.PA) | 0 % | 1.66 | 56.5 million | 7.68 |
| Saint Jean Groupe (SABE.PA) | –3.98 % | 17.5 | 55.9 million | – |
| Herige (ALHRG.PA) | –1.07 % | 18 | 60.2 million | – |
While Adocia remains the only stock in the group to trade below €3, its peers have shown comparatively steadier performance, with Groupe Ldlc posting a modest gain and Hotelim and Catana remaining flat.
Company Overview
Adocia SAS, founded in 2005 and headquartered in Lyon, France, operates as a clinical‑stage biotechnology firm focused on the development of therapeutic proteins and peptides for metabolic disorders such as diabetes. The company’s proprietary BioChaperone platform utilizes novel polymers, oligomers, and small molecules to enhance both the efficacy and safety profiles of therapeutic proteins.
Adocia’s pipeline encompasses several insulin formulations—including BioChaperone Lispro U100/U200, HinsBet U100, and BioChaperone Combo—as well as prandial combinations such as BioChaperone Pramlintide Insulin. Additional products under development include BioChaperone Glargine Dulaglutide and Glargine Liraglutide, which merge insulin glargine with GLP‑1 analogues, and BioChaperone Teduglutide, targeting short bowel syndrome. The company is also pursuing a BioChaperone Glucagon GLP‑1 formulation aimed at obesity treatment.
Strategic collaborations, notably with Tonghua Dongbao Pharmaceutical Co., Ltd., reinforce Adocia’s position in the market. The firm is publicly listed on the NYSE Euronext Paris exchange and maintains its corporate website at www.adocia.com .
